Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Paratek Pharmaceuticals, Inc. PRTK
$1.89
+$0.07 (3.57%)
На 18:00, 12 мая 2023
+958.20%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
105972070.00000000
-
week52high
3.65
-
week52low
1.29
-
Revenue
150788000
-
P/E TTM
-1
-
Beta
1.59377100
-
EPS
-1.15000000
-
Last Dividend
31.97300000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 06 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 17 мар 2022 г. |
| WBB Securities | Strong Buy | Buy | 10 февр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 09 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 21 июн 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Woodrow Adam | D | 651284 | 6750 | 21 дек 2022 г. |
| Loh Evan | D | 1208198 | 23489 | 21 дек 2022 г. |
| Haskel William M. | D | 407800 | 7007 | 21 дек 2022 г. |
| Brenner Randall B. | D | 335312 | 4539 | 21 дек 2022 г. |
| BIGHAM MICHAEL | D | 1209702 | 15750 | 21 дек 2022 г. |
| Woodrow Adam | A | 658034 | 22500 | 20 дек 2022 г. |
| Loh Evan | A | 1231687 | 52500 | 20 дек 2022 г. |
| Haskel William M. | A | 414807 | 15000 | 20 дек 2022 г. |
| Brenner Randall B. | A | 339851 | 15000 | 20 дек 2022 г. |
| BIGHAM MICHAEL | A | 1225452 | 45000 | 20 дек 2022 г. |
Новостная лента
7 Growth Stocks That Are Too Cheap to Ignore Right Now
InvestorPlace
10 мая 2023 г. в 15:31
Although the equities sector recovered reasonably well from 2022's harsh glare, rising headwinds force consideration of cheap growth stocks to buy now. Essentially, some enterprises with upside potential may be overlooked by other investors, presenting contrarian opportunities.
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
GlobeNewsWire
01 мая 2023 г. в 08:30
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call will dial: 800-920-3371 and international investors will dial: +1-212-231-2909. The conference ID is 22026760. Investors can also access the call at: https://viavid.webcasts.com/starthere.jsp?ei=1611304&tp_key=5fe62a51b9 About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights. Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States. Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.
Paratek Pharmaceuticals, Inc. (PRTK) Q4 2022 Earnings Call Transcript
Seeking Alpha
16 мар 2023 г. в 14:14
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Sarah Higgins - VP, Finance, and Principal Accounting Officer Evan Loh - CEO Adam Woodrow - President and Chief Commercial Officer Randall Brenner - Chief Development and Regulatory Officer Conference Call Participants Suji Jeong - Jefferies Robert Hazlett - BTIG Ed Arce - H.C. Wainwright Operator Greetings, and welcome to the Paratek Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Call.
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
GlobeNewsWire
08 мар 2023 г. в 08:30
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2022.
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
GlobeNewsWire
21 ноя 2022 г. в 16:05
BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that Evan Loh, M.D., chief executive officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30 at 9:15 a.m. ET.